Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC

Clinical trial NCT04371796 · UNKNOWN

Trial details

NCT number: NCT04371796
Sponsor: Sichuan Cancer Hospital and Research Institute
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Lung Diseases Neoplasms Respiratory Tract Diseases Thoracic Neoplasms Non-small-cell Lung Cancer

Start date: 2020-05-10
Primary completion: 2021-06-30
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.